Clinical Data From Full Phase 1 Cohort Of Investigational Sotorasib Published In New England Journal Of Medicine

THOUSAND OAKS, Calif., Sept. 20, 2020 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that updated data from the full Phase 1 cohort of the CodeBreaK 100 clinical study, evaluating sotorasib (proposed INN for AMG 510) in 129 patients across

Neurosteroid antidepressants on horizon

More than 14 million Americans suffer from clinical depression, yet one in three doesn’t experience relief from approved antidepressant drugs. A new treatment approach involving drugs called neurosteroids is on the horizon, however. Neurosteroids occur